Patent ID: 11857611
Assignee: GEOVAX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A

Claim 12:
13. A recombinant modified vaccinia Ankara (MVA) viral vector comprising:
i) a first nucleic acid encoding a Plasmodium falciparum CSP21R immunogenic polypeptide comprising the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence at least 95% identical thereto,
ii) a second nucleic acid sequence encoding a Plasmodium falciparum Pfs230 immunogenic polypeptide comprising the amino acid sequence of SEQ ID NO: 6, or an amino acid sequence at least 95% identical thereto, further comprising a transmembrane domain of a glycoprotein (GP) of Marburg virus, and
iii) a third nucleic acid encoding a Marburg virus VP40 matrix protein comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence at least 95% identical thereto;
wherein the first nucleic acid, the second nucleic acid sequence, and the third nucleic acid sequence are each under the control of a promoter compatible with poxvirus expression systems.